JPWO2019150341A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2019150341A5
JPWO2019150341A5 JP2020542141A JP2020542141A JPWO2019150341A5 JP WO2019150341 A5 JPWO2019150341 A5 JP WO2019150341A5 JP 2020542141 A JP2020542141 A JP 2020542141A JP 2020542141 A JP2020542141 A JP 2020542141A JP WO2019150341 A5 JPWO2019150341 A5 JP WO2019150341A5
Authority
JP
Japan
Prior art keywords
acid
formula
lipoic
pharmaceutically acceptable
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020542141A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021512876A5 (https=
JP2021512876A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/050901 external-priority patent/WO2019150341A1/en
Publication of JP2021512876A publication Critical patent/JP2021512876A/ja
Publication of JP2021512876A5 publication Critical patent/JP2021512876A5/ja
Publication of JPWO2019150341A5 publication Critical patent/JPWO2019150341A5/ja
Pending legal-status Critical Current

Links

JP2020542141A 2018-02-05 2019-02-05 抗ムスカリン薬又は抗コリン作動薬及びリポ酸の組合せ物並びにその使用 Pending JP2021512876A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN201841004306 2018-02-05
IN201841004306 2018-02-05
IN201841008091 2018-03-05
IN201841008091 2018-03-05
PCT/IB2019/050901 WO2019150341A1 (en) 2018-02-05 2019-02-05 Combination of an antimuscarinic or an anticholinergic agent and lipoic acid and uses thereof

Publications (3)

Publication Number Publication Date
JP2021512876A JP2021512876A (ja) 2021-05-20
JP2021512876A5 JP2021512876A5 (https=) 2022-02-02
JPWO2019150341A5 true JPWO2019150341A5 (https=) 2022-02-02

Family

ID=67480013

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020542141A Pending JP2021512876A (ja) 2018-02-05 2019-02-05 抗ムスカリン薬又は抗コリン作動薬及びリポ酸の組合せ物並びにその使用

Country Status (13)

Country Link
US (2) US20200375961A1 (https=)
EP (1) EP3749303A4 (https=)
JP (1) JP2021512876A (https=)
KR (1) KR20200118128A (https=)
AU (1) AU2019214557A1 (https=)
BR (1) BR112020015436A2 (https=)
CA (1) CA3089894A1 (https=)
IL (1) IL276350A (https=)
MX (1) MX2020008173A (https=)
RU (1) RU2020122659A (https=)
SG (1) SG11202006492SA (https=)
WO (1) WO2019150341A1 (https=)
ZA (1) ZA202004058B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3522873B1 (en) * 2016-10-04 2022-03-16 Cellix Bio Private Limited Compositions and methods for the treatment of xerostomia
CA3116589A1 (en) 2018-10-26 2020-04-30 Ocuphire Pharma, Inc. Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders
WO2020144546A1 (en) * 2019-01-12 2020-07-16 Cellix Bio Private Limited Combination of selective alpha-adrenergic receptor agonist or an anticholinergic agent and lipoic acid and uses thereof
CN113387923A (zh) * 2020-03-13 2021-09-14 诺华股份有限公司 硫辛酸胆碱酯盐的药物组合物及使用其的治疗方法
IL298476A (en) * 2020-05-26 2023-01-01 Cellix Bio Private Ltd Pharmaceutical formulations of pilocarpine r-(+)-lipoate
WO2022080529A1 (ko) * 2020-10-15 2022-04-21 경상대학교병원 침분비 저하증 예방 또는 치료용 약학적 조성물 및 건강기능식품
WO2023052977A1 (en) * 2021-09-29 2023-04-06 Avaca Pharma Private Limited Compositions, methods and uses thereof
WO2023052974A1 (en) * 2021-09-29 2023-04-06 Avaca Pharma Private Limited Ocular compositions and methods for the treatment of ophthalmic diseases and disorders
CN119454701A (zh) * 2022-01-18 2025-02-18 苏州普乐康医药科技有限公司 一种含西维美林的眼用制剂及其制备方法和应用
EP4469047A4 (en) * 2022-01-25 2026-03-04 Biotheravision Inc AQUEOUS COMPOSITIONS OF CEVIMELINE AND METHODS OF USE
WO2023143575A1 (zh) * 2022-01-29 2023-08-03 南京济群医药科技股份有限公司 一种m-胆碱受体激动剂化合物及其制备方法和用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3608073A (en) * 1968-07-16 1971-09-21 Barnes Hind Pharm Inc Emulsion of pilocarpine for ophthalmic use
CN1960735B (zh) * 2004-05-20 2015-07-29 代阿麦迪卡股份有限公司 药物组合在治疗胰岛素抗性中的应用
JP2006070027A (ja) * 2004-08-06 2006-03-16 Dai Ichi Seiyaku Co Ltd 口腔粘膜投与剤
US20110150974A1 (en) * 2004-08-06 2011-06-23 Daiichi Pharmaceutical Co., Ltd. Agent For Oral Mucosal Administration
WO2007064755A2 (en) * 2005-11-30 2007-06-07 Endo Pharmaceuticals Inc. Treatment of xerostomia with a sulfur-containing antioxidant
UA86441C2 (ru) * 2007-03-30 2009-04-27 Акционерное Общество Открытого Типа "Галичфарм" (2-гидроксиэтил)триметиламмония тиоктат (холина тиоктат), имеющий гепатопротекторное, гипоаммониемическое и детоксицирующее действие, способ его получения, фармацевтическая композиция на его основе
US20090263467A1 (en) * 2008-04-21 2009-10-22 Hemant Narahar Joshi Combination drug therapy using orally dissolving film or orally disintegrating tablet dosage forms to treat dry mouth ailments
EP2821405B1 (en) * 2009-06-15 2016-04-13 Encore Health, LLC Choline esters for treating presbyopia and cataract
JP5595513B2 (ja) * 2009-11-12 2014-09-24 アカシア ファーマ リミテッド 口腔乾燥症の治療のためのベタネコールの使用
US10507245B2 (en) * 2012-07-19 2019-12-17 Luis Felipe Vejarano Restrepo Ophthalmic formulation and method for ameliorating presbyopia
JP2015533174A (ja) * 2012-10-11 2015-11-19 セラヴィダ,インコーポレイテッド ピロカルピンの医薬製剤
KR101586789B1 (ko) * 2012-12-28 2016-01-19 주식회사 종근당 양이온성 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
US9427144B2 (en) * 2014-01-03 2016-08-30 Ophthalmx Llc Methods and systems for detecting ophthalmic disease
CA2936146A1 (en) * 2014-01-06 2015-07-09 Stealth Biotherapeutics Corp Methods and compositions for preventing or treating dominant optic atrophy
EP3522873B1 (en) * 2016-10-04 2022-03-16 Cellix Bio Private Limited Compositions and methods for the treatment of xerostomia
CA3081553C (en) * 2017-11-17 2022-11-15 Cellix Bio Private Limited Compositions and methods for the treatment of eye disorders
WO2020144546A1 (en) * 2019-01-12 2020-07-16 Cellix Bio Private Limited Combination of selective alpha-adrenergic receptor agonist or an anticholinergic agent and lipoic acid and uses thereof

Similar Documents

Publication Publication Date Title
JP2021512876A5 (https=)
RU2020122659A (ru) Комбинация антимускаринового или антихолинергического средства и липоевой кислоты и ее применения
JPWO2019150341A5 (https=)
JP7133680B2 (ja) バイオアベイラビリティが高いアルボシジブプロドラッグ
US7550613B2 (en) Compounds
BRPI0708071A2 (pt) derivados de catecolamina deuterada e medicamentos compreendendo os ditos compostos
JP2016188218A (ja) 3−(3−ジメチルアミノ−1−エチル−2−メチル−プロピル)−フェノールの塩または共結晶
JP2004526745A5 (https=)
AU2012338362B2 (en) Tricyclic compounds, compositions comprising them and uses thereof
RU2011109084A (ru) Терапевтические композиции, содержащие мацитентан
BR112019011640B1 (pt) Compostos conjugados de d-metilfenidato, composições que compreendem os mesmos e kit farmacêutico que compreende as ditas composições
TWI534125B (zh) Novel compounds, salts thereof or solvates thereof, and pharmaceutical compositions and pharmaceutical products containing the same
DK2523669T3 (en) COMBINATION, KIT AND PROCEDURE TO REDUCE INTRAOCULAR PRESSURE
CN111801013A (zh) 小分子核受体调节剂的酰胺前药
JP2025163212A5 (https=)
CN112384214A (zh) 作为可溶性鸟苷酸环化酶激活剂的烷氧基吡唑
US8440639B2 (en) Combination compositions for reducing intraocular pressure
CA2973178C (en) Bupivacaine derivatives and their use in the treatment of inflammation and pain
CN109310669B (zh) 氨基甲酸酯化合物用于预防或治疗三叉神经痛的用途
RU2022104493A (ru) Композиция и способы лечения анальных и ректальных нарушений
JPWO2023205233A5 (https=)
JPWO2023205245A5 (https=)
JPWO2023205237A5 (https=)
JPWO2023205241A5 (https=)
AU2002327041A2 (en) Ophthalmologic treatment methods using selective iNOS inhibitors